These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24375965)

  • 1. Generalization and extrapolation of treatment effects from clinical studies in rheumatoid arthritis.
    Nair SC; Kievit W; Janse RW; Bijlsma JW; Fransen J; Lafeber FP; Welsing PM
    Arthritis Care Res (Hoboken); 2014 Jul; 66(7):998-1007. PubMed ID: 24375965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
    Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
    J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X; Nordström D; Rodriguez M; Rubbert A; Sarzi-Puttini P; Wouters JM; Woolley JM; Wright N; Lawrence C; Appleton B
    J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absent "Window of Opportunity" in smokers with short disease duration. Data from BARFOT, a multicenter study of early rheumatoid arthritis.
    Söderlin MK; Bergman S;
    J Rheumatol; 2011 Oct; 38(10):2160-8. PubMed ID: 21807778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.
    Welsing PM; Fransen J; van Riel PL
    Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treat-to-target approach in daily clinical practice in Pakistani patients with early Rheumatoid Arthritis.
    Farman S; Ahmad NM; Saeed MA; Asad K; Shabbir G
    J Coll Physicians Surg Pak; 2015 Feb; 25(2):129-33. PubMed ID: 25703758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
    Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritis.
    Behrens F; Tony HP; Alten R; Kleinert S; Scharbatke EC; Köhm M; Gnann H; Tams J; Greger G; Burkhardt H
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1608-16. PubMed ID: 23609999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.
    Verstappen SM; van Albada-Kuipers GA; Bijlsma JW; Blaauw AA; Schenk Y; Haanen HC; Jacobs JW;
    Ann Rheum Dis; 2005 Jan; 64(1):38-43. PubMed ID: 15130899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The methotrexate therapeutic response in rheumatoid arthritis.
    Ortendahl M; Holmes T; Schettler JD; Fries JF
    J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials.
    Smolen JS; Aletaha D; Grisar JC; Stamm TA; Sharp JT
    Ann Rheum Dis; 2010 Jun; 69(6):1058-64. PubMed ID: 19717399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice.
    Linde L; Sørensen J; Østergaard M; Hetland ML
    J Rheumatol; 2013 Sep; 40(9):1479-86. PubMed ID: 23818719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.